Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. - Wikidata - awgldk - TriplyDB

Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.

Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.

http://www.wikidata.org/entity/Q44371344

about

Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough Globus pharyngeus: a review of its etiology, diagnosis and treatment Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough: a Cochrane systematic review.Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors Efficacy of esomeprazole for treatment of poorly controlled asthma.ACG practice guidelines: esophageal reflux testing.Discussing the influence of electrode location in the result of esophageal prolonged pH monitoring.What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsia.Review article: diagnosis and management of night-time reflux.Nocturnal acid breakthrough - approach to management.Emerging drugs for gastro-oesophageal reflux disease.Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?Treatment of uncomplicated reflux disease Therapy Insight: gastroesophageal reflux disease and laryngopharyngeal reflux.An update on the available treatments for non-erosive reflux disease.Review article: the opportunities and benefits of extended acid suppression.Acid aspiration-induced airways hyperresponsiveness in mice.Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease.Acid peptic diseases: pharmacological approach to treatment.Barrett's esophagus: proton pump inhibitors and chemoprevention I.Gastroesophageal reflux disease and sleep disturbances.Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease.Refractory gastroesophageal reflux disease: advances and treatment.Ambulatory pH Monitoring: New Advances and Indications.Can Nocturnal Acid-breakthrough Be Reduced by Long-acting Proton Pump Inhibitors?Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough.Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey.Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy.Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study.

P2860

Q24240662-9E1207F0-30F4-4DFF-AE61-02AC08014E58 Q24246606-6E6F88C5-5D35-48F1-87E6-47E5AEC2781D Q27006482-B1F49099-1511-489A-9CBF-E3869D3DC0BC Q33248384-92C3F28A-9812-4704-AB82-E7676565BEF9 Q33337244-02AF86AD-9DA0-4908-A76F-8BFFBB7E4D90 Q33428499-7D8B5045-C2BC-426F-8B65-51652D3E5A6A Q34576807-944BB031-89A7-406C-B69F-5C6F6EC33EF2 Q35141042-70B02493-6D03-48D8-8481-44DBF2C4704A Q35873855-2CBAE591-42FB-4D02-A03C-090ED7972259 Q35939808-72074F97-74C2-4FF8-AA05-F176F6B1F01F Q36073758-0E12BFBA-BD8C-43F3-A18D-915BA9F8EE12 Q36150665-7E4FC2B0-AC31-4614-8736-103E4AEFE6FB Q36191254-517DF555-733D-4F93-9A2B-182402F9EFAC Q36204260-9B9F4DF6-539B-4E48-B42A-C38D6907E8D2 Q36331238-99FA185E-6837-4F43-9039-13DB847B9FE9 Q36349598-E562BF95-8D94-47D7-827D-1D04B82348D3 Q36478875-1E109708-AC9F-4578-8184-51E9B0148227 Q37475073-2E451B52-A0F5-4D11-836E-9DD73E7E1961 Q37740015-55B6C315-014C-4022-975F-864257E17BCB Q37913063-43522DE5-59F1-447F-9D3A-98DF388C3986 Q37939281-7F18E093-5A0B-4F3C-BF67-6D7E6C80CB80 Q38010650-25C70C7C-73C5-4F67-81FC-2A97D0B968A5 Q38151800-F1D16B8B-C3B2-4B9E-B265-C429CF891511 Q38205522-BEF8177B-4523-4F34-97D8-EE801BCDC83B Q40274540-4FAB0C2F-CF7C-4981-8751-544E838E8D1D Q42365931-3D991C3F-4A2E-43B5-BE51-F2BC64A328FC Q44895190-E4FE310C-A8AE-4CAA-94A5-71346FD6D67C Q46522095-0DEC2D37-48F6-4B52-AA57-95E6D7EAC6C3 Q46539046-21B4E4B6-55CD-4A2A-9870-A05B4D8BBDBB Q46946133-C704AADC-44DE-4198-9033-1D1180646E57 Q51500147-CA5B6F22-5FF8-4289-BB74-F08B3F0D9208

P2860

Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.

http://www.wikidata.org/entity/Q44371344

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Nocturnal acid breakthrough: c ...... with esophageal acid exposure.

@en

Nocturnal acid breakthrough: c ...... with esophageal acid exposure.

@nl

type

label

Nocturnal acid breakthrough: c ...... with esophageal acid exposure.

@en

Nocturnal acid breakthrough: c ...... with esophageal acid exposure.

@nl

prefLabel

Nocturnal acid breakthrough: c ...... with esophageal acid exposure.

@en

Nocturnal acid breakthrough: c ...... with esophageal acid exposure.

@nl

P1433

Q44371344-F0ECFF8A-1FC2-4A62-B9E5-C7B218616A65

P1476

Q44371344-CCA307BB-C601-4E3B-A1BE-4B4AE71F6B76

P2093

Q44371344-75C8D521-09AE-401B-A15D-61D010E58B6E

Q44371344-A79343A6-BE1B-4FFB-87E2-85AC2C1CB464

Q44371344-B4080057-5ADF-467C-9BFF-C9387894AD09

Q44371344-BC5CC8F1-9B8C-4D10-A443-3BFE991C9077

P2860

Q44371344-26F4715B-9579-412C-A986-5CA659706AB3

Q44371344-DEBB10F7-6604-4AFB-B099-0622159B80AD

Q44371344-F1801009-2C13-49DE-8480-C2DC7EFDCE41

Q44371344-F67835A1-C3F2-4E7F-A5A1-C64D5BDA1A94

P304

Q44371344-063FEC1B-DB9A-4A97-95DE-1973F247420A

P31

Q44371344-0E8D2DDC-EED5-4B89-A8A4-B866A1B5F7A8

P356

Q44371344-EF873A55-A929-4766-B8D3-31FF20A6C90E

P407

Q44371344-7DDED80D-A20A-42EE-A47A-AA3F8000829A

P433

Q44371344-F7D56F70-FCC6-4DB3-B4C6-38274E76F4C1

P478

Q44371344-852A1269-1FAE-44FC-B893-A322F93738F6

P577

Q44371344-08ACDB22-FE3F-4DF4-AF9E-F79DEB80C3E1

P698

Q44371344-A1F23BB8-B459-4F55-8B69-CB04416A0E01

P356

J.1572-0241.2003.07304.X

P1433

The American Journal of Gastroenterology

P1476

Nocturnal acid breakthrough: c ...... with esophageal acid exposure.

@en

P2093

Joel E Richter

http://www.w3.org/2001/XMLSchema#string

Michael F Vaezi

http://www.w3.org/2001/XMLSchema#string

Tina M Ours

http://www.w3.org/2001/XMLSchema#string

W Keith Fackler

http://www.w3.org/2001/XMLSchema#string

P2860

Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors

Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.

Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonists.

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.

P304

545-550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2003.07304.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12650785

http://www.w3.org/2001/XMLSchema#string